Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex
NCT07756138
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Epidermolysis Bullosa Simplex
Interventions
DRUG:
Filsuvez
Sponsor
Stanford University